Stereoselective synthesis and β-blocking activity of substituted (E)- and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl)oximino]-2,3-dihydro-1,8-naphthyridine. Potential antihypertensive agents. Part VI-Reference-Cited by-同舟云学术

Stereoselective synthesis and β-blocking activity of substituted (E)- and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl)oximino]-2,3-dihydro-1,8-naphthyridine. Potential antihypertensive agents. Part VI

Published:1998-12 Issue:12 Volume:32 Page:955-963
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Ferrarini P.L.,Mori C,Badawneh M,Manera C,Saccomanni G,Calderone V,Scatizzi R,Barili P.L.

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference12 articles.

1. Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral .beta.-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene

2. New chiral and isomeric cyclopropyl ketoxime propanolamine derivatives with potent .beta.-adrenergic blocking properties

3. Synthesis and β-blocking activity of (E)- and (Z)-iminoethers of 1,8-naphthyridine. Potential antihypertensive agents. 4

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrode behavior of some triazole derivatives using convolutive voltammetry, chronoamperometry and differential pulse polarography techniques;Chemical Papers;2019-04-24

2. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities;Archiv der Pharmazie;2015-11-09

3. Indenopyrazole oxime ethers: Synthesis and β1-adrenergic blocking activity;European Journal of Medicinal Chemistry;2015-03

4. Synthesis of fluorene and/or benzophenone O-oxime ethers containing amino acid residues and study of their cardiovascular and antibacterial effects;Medicinal Chemistry Research;2014-03-02

5. Biological evaluation of 10-(diphenylmethylene)- 4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione derivatives;Open Life Sciences;2009-09-01